Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

Julio Arroyo, West Columbia

Infectious Diseases Research Clinic / Indiana Univ Hosp, Indianapolis

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

Univ of Miami School of Medicine, Miami

Ohio State Univ Hosp Clinic, Columbus

Univ of Washington, Seattle